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Abstract
Objective: The first aim of this study was to assess 25-hydroxy vitamin D (25OHD) concentrations in women with type 1
diabetes (T1DM) during pregnancy, post-delivery and also foetal (cord blood) 25OHD concentrations and to examine
relationships between these. The second aim of the study was to investigate potential interactions between maternal body
mass index (BMI) and foetal vitamin D status. A further study aim was to examine potential relationships between maternal
25OHD and glycosylated haemoglobin (HbA1c) throughout pregnancy.
Research Design and Methods: This was an observational study of 52 pregnant controls without diabetes and 65 pregnant
women with T1DM in a university teaching hospital. Maternal serum 25OHD was measured serially throughout the
pregnancy and post-delivery. Cord blood 25OHD was measured at delivery. 25OHD was measured by liquid
chromatography tandem mass spectrometry (LC-MS/MS).
Results: Vitamin D deficiency (25OHD,25 nmol/L) was apparent in both the T1DM subjects and controls at all 3 pregnancy
trimesters. Vitamin D levels in all cord blood were,50 nmol/L. Maternal 25OHD correlated positively with cord 25OHD at all
3 trimesters in the T1DM group (p= 0.02; p,0.001; p,0.001). 25OHD levels within cord blood were significantly lower for
women with diabetes classified as obese vs. normal weight at booking [normal weight BMI ,25 kg/m2 vs. obese BMI
.30 kg/m2 (nmol/L6SD); 19.93611.15 vs. 13.7364.74, p= 0.026]. In the T1DM group, HbA1c at booking was significantly
negatively correlated with maternal 25OHD at all 3 trimesters (p= 0.004; p = 0.001; p= 0.05).
Conclusion: In T1DM pregnancy, low vitamin D levels persist throughout gestation and post-delivery. Cord blood vitamin D
levels correlate with those of the mother, and are significantly lower in obese women than in their normal weight
counterparts. Maternal vitamin D levels exhibit a significant negative relationship with HbA1c levels, supporting a potential
role for this vitamin in maintaining glycaemic control.
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Introduction
It is well established that vitamin D plays a primary role in bone
health, with severe vitamin D deficiency known to cause rickets in
children and osteomalacia in adults [1]. Vitamin D has also been
linked to a wide variety of other non-bone health outcomes such
as; cardiovascular disease, cancer, autoimmune diseases and type 1
and type 2 diabetes mellitus (T1DM, T2DM; [2]).
Vitamin D status is assessed by measuring circulating concen-
trations of 25-hydroxy vitamin D (25OHD). In relation to bone
health, a 25OHD level of ,25 nmol/l is currently defined as
deficient [3]; however, the cut-off level for sufficiency remains
unclear. Holick [4] suggests that for extraskeletal health, sufficien-
cy is achieved at vitamin D levels.75 nmol/l. Hypovitaminosis D
is commonly seen in both pregnant and non-pregnant women
worldwide [5]; with many factors impacting on vitamin D status,
including; exposure to sunlight, skin colour, season, latitude and
obesity, among others [6].
In the absence of environmental and behavioural factors,
25OHD has been found to remain unchanged during pregnancy
[7], while other evidence has indicated that 25OHD levels decline
slightly with advancing gestation [8]. During pregnancy, 25OHD
diffuses across the placental barrier, meaning the foetus relies
entirely on the vitamin D status of the mother [9]. Cord
concentrations are lower than maternal concentrations, therefore,
if the mother is deficient so too will be the foetus [9]. Despite the
lack of change/decline in 25OHD levels, levels of the biologically
active vitamin D metabolite, 1,25 dihydroxy vitamin D
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[1,25(OH)2D], are known to increase by 100% or more during
pregnancy [7,10]. This rise begins at 10–12 weeks gestation and
reaches a maximum in the third trimester [10]. Increased synthesis
of the active vitamin D form is due to the enhanced production of
1a-hydroxylase in the decidua and placenta, as well as an
oestrogen-dependent increase in vitamin D binding protein [7].
This apparent rise in 1,25(OH)2D has led to the suggestion that
pregnant women may require higher cellular exposure to active
vitamin D during the second and third trimesters, and has been
interpreted by some as providing evidence for its potential role in
obstetric well-being [8].
Vitamin D deficiency has been linked to multiple adverse
perinatal outcomes in pregnancy including; pre-eclampsia, gesta-
tional diabetes, low birth weight, bacterial vaginosis, pre-term
delivery and caesarean section [7,11]. It has been speculated that
some adverse perinatal outcomes may be due to the immuno-
modulatory properties of vitamin D, which may assist in the
appropriate immune response to the placenta [7]. Vitamin D is
also directly involved in the production of cathelicidin: antimicro-
bial peptides, which could potentially prevent infection during
pregnancy [12].
Maternal hypovitamosis D has also been reported to be
associated with a number of adverse bone and non-bone health
outcomes in off-spring. There have been reports of increased
incidence of rickets cases in children born to vitamin D deficient
mothers [13]. The results of a large recently published prospective
study has, however, found no evidence of an association between
the maternal vitamin D status in pregnancy and late childhood
bone mineral content (average age 10 yrs) [14]. Importantly, this
cohort was largely of white European origin and therefore, less at
risk of vitamin D deficiency [15]; furthermore, the authors
counselled that their findings should not be taken to mean that
individual 25OHD concentrations are not an important determi-
nant of bone health, and, moreover, that their study was not
designed to examine non-bone health outcomes [14]. Additionally,
there is emerging evidence demonstrating an association between
foetal and early childhood vitamin D deficiency and later adult
disease processes, such as multiple sclerosis, cardiovascular disease,
schizophrenia, certain cancers and other autoimmune diseases
such as T1DM and lupus [16].
Numerous studies have established an inverse relationship
between circulating levels of 25OHD and measures of adiposity
[17]. The most likely mechanism underlying this, is the ability of
subcutaneous fat to sequester cutaneously synthesized D3 [18], the
25OHD precursor. While it has been speculated that vitamin D
deficiency may be causal in the development of adiposity and,
potentially, its co-morbidities, a recent study using genetic markers
as instrumental variables in bi-directional Mendelian randomiza-
tion analysis has provided evidence that a higher BMI leads to
lower 25OHD and that the likelihood of lower 25OHD increasing
BMI is small [19]. These findings led the study authors to conclude
that population level interventions to reduce BMI would be
expected to decrease the prevalence of vitamin D deficiency.
Studies in women without diabetes [20,21] have reported
significantly reduced cord 25OHD levels in women classified as
obese vs. normal weight pre-pregnancy.
Women with T1DM have an increased risk of pregnancy
complications including; miscarriage, congenital malformations,
macrosomia, still birth, pre-term birth and pre-eclampsia [22],
some of which have been reported to be associated with vitamin D
deficiency in pregnancy. Further, it has been suggested that
vitamin D can alter glucose and insulin metabolism, and,
therefore, impact on energy available to the foetus [11]. There
are numerous reports supporting a role for vitamin D in
promoting insulin sensitivity and maintaining glycaemic control
in T2DM, while the evidence for a similar role in T1DM is more
limited.
The first aim of this observational study was to assess 25OHD
concentrations in women with T1DM during pregnancy, post-
delivery and also foetal (cord blood) 25OHD concentrations, and
to examine relationships between these. The second aim of the
study was to investigate potential interactions between maternal
BMI and foetal vitamin D status. A further study aim was to
examine potential relationships between maternal 25OHD and
glycosylated haemoglobin (HbA1c) throughout pregnancy.
Methods
Ethics Statement
The study was approved by the Office of research Ethics
Committee Northern Ireland (REC 07/NIR02/1360).
Settings and Participants
Sixty-five pregnant women with T1DM and fifty-two pregnant
controls without diabetes were recruited from the Royal Jubilee
Maternity Hospital before 14 weeks of gestation. The subjects
were recruited between October 1997-February 2000 [23]. All
participants had a single pregnancy during the study period and all
had live births and singleton pregnancies [23]. Written consent
was obtained from all patients. Exclusion criteria for the control
subjects were as follows: presence of glucose intolerance on routine
screening [24], previous gestational diabetes mellitus, or a first-
degree relative with diabetes mellitus. All T1DM subjects were
confirmed as type 1 before pregnancy. All study participants were
white in origin.
In all subjects, blood samples were obtained at booking and at
20, 28, 32, 36, and 38 weeks of gestation and within 48 hours post-
delivery. Gestational age was estimated by ultrasound measure-
ments and also from the date of the last menstrual period. Levels of
HbA1c ,6.5% (47.5 mmol/mol) were considered to be normal in
pregnancy. Clinical, obstetric, and neonatal descriptive variables
are shown in Table 1. Infants were assigned to birth weight
percentiles according to gestational age, sex, and current British
growth standards [25]. The same approach was used to adjust
neonatal BMI (weight/height2) for age at examination and sex.
The birth weight SD score (SDS) represents the number of
standard deviations (S.Ds) that the birth weight is from the mean
for British births of that gestational age and sex. Preeclampsia
(proteinuric pregnancy-induced hypertension) was defined using
the accepted criteria of the International Society for the Study of
Hypertension in Pregnancy as proposed by Davey and MacGil-
livray [26]. Patients with a history of hypertension, proteinuric
renal disease prior to pregnancy, or who had a urinary albumin
.20 g/dL or an albumin/creatinine ratio .2.0 mg/mmol
recorded at less than 20 weeks gestation were excluded by
definition. Neonatal anthropometric measures were performed
within 12 to 72 hours of birth and included triceps and
subscapular skinfold thickness.
Cord Blood Collection
Cord blood was collected from 56 of the babies born to women
with T1DM vs. 25 from control women. Twenty millilitres of
venous cord blood was taken from the cord immediately after
clamping and cutting of the umbilical cord.
Biochemical Assessment
HbA1c was recorded by three different methods during the time
of the study. All the previous HbA1c results were adjusted to the
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most recent method [high-performance liquid chromatography;
auto A1c HA 8140 analyzer (Arkray-Menarini Diagnostics,
Berkshire, UK); intra-assay coefficient of variation, 3%; the
Diabetes Control and Complications Trial aligned results refer-
ence range, ,6.5%], thus allowing numeric comparison of the
results.
Total 25OHD Analysis
Levels of 25OHD2&3 were measured by means of liquid
chromatography tandem mass spectrometry (LC-MS/MS) and
results are presented as total 25OHD.
Standards/calibrators, quality controls, and internal
standards. Working standards were prepared by diluting
commercially available 25OHD2&3 bi-level serum controls
(Chromsystems, Munchen, Germany) into horse serum (Sigma-
Aldrich Co Ltd, Poole, UK). Low, medium and high quality
control samples were prepared in a similar manner. Hexadeuter-
ated analogs (d6-25OHD2; Medical Isotopes, USA; d6-25OHD3;
Synthetica AS, Oslo, Norway) were diluted with 80% (v/v)
methanol in isopropanol to produce final concentrations of
625 nmol/L.
Sample preparation. Sample preparation was performed
via a liquid/liquid extraction procedure. In brief, equal amounts of
d6-25OHD2 and d6-25OHD3 were added to 150 mL of each of the
calibrators, controls and patient samples. Methanol was added to
precipitate proteins, followed by hexane to extract vitamin D.
Samples were vortex-mixed for 30 seconds and centrifuged for 5
minutes at 13,000 g. The organic layer was transferred into
maximum recovery vials (Waters, UK), evaporated under nitrogen
gas, and reconstituted in 75 mL of 70% (v/v) methanol in water.
Following a brief vortex-mix, vials were placed into the LC-MS/
MS sample manager, which was kept at 10uC, and 20 mL of each
sample was injected into the system.
LC-MS/MS analysis. Sample analysis was performed using
an automated LC-MS/MS system, which consisted of an
ACQUITY UPLCH (Waters Corporation, UK) coupled to a
WatersH Xevo TQ-SH tandem quadrupole mass spectrometer.
Chromatographic separation of 25OHD2&3 and d6-25OHD2&3
was achieved using a Waters ACQUITY UPLC BEH Phenyl
column (2.1650 mm; 1.7 mm particle size), maintained at a
temperature of 35uC. The mobile phases consisted of 2 mmol/L
ammonium acetate (w/v) (Sigma-Aldrich Co Ltd, Poole, UK) and
0.1% formic acid (v/v) (Fisher Scientific, UK) in water (A) and
methanol [LC-MS-grade; Fisher Scientific, UK (B)]. The flow rate
was set to 0.450 mL/min throughout.
A WatersH Xevo TQ-SH tandem quadrupole mass spectrometer
was used in positive electrospray ionisation mode. Instrument
analysis time per sample was 4.5 minutes. The multiple-reaction
monitoring transitions used were: m/z 395.4.269.3 for 25OHD2,
m/z 383.3.257.3 for 25OHD3, m/z 401.3.269.2 for d6-
25OHD2, and m/z 389.35.263.3 for d6-25OHD3. Typical
elution times for 25OHD2, 25OHD3, d6-25OHD2 and d6-
25OHD3, were 2.90, 2.81, 2.89 and 2.80 minutes, respectively.
System operation and data acquisition were controlled using
MassLynx 4.1 software with auto data processing by the
TargetLynx Application Manager.
Table 1. Clinical characteristics and pregnancy outcomes of study participants at baseline.
Characteristic/Outcome Control group (n=52) T1DM group (n =65) p value
Maternal Characteristic
Age (y)* 29.665.5 29.764.9 0.99
BMI at booking (kg/m2)* 25.765.4 27.665.2 0.07
Parity
0 17/52 (32.7%) 28/65 (43.1%) 0.25
1 13/52 (25%) 21/65 (32.3%) 0.39
$2 22/52 (42.3%) 16/65 (24.6%) 0.04
Previous miscarriage 11/52 (21.2%) 24/65 (36.9%) 0.10
Cigarette smoking 21/52 (40.4%) 7/65 (10.8%) ,0.001
HbA1c* 4.8060.23 6.9360.90 ,0.001
Pregnancy outcomes
Preeclampsia 2/52 (3.8%) 10/65 (15.4%) 0.04
Delivery gestational age (wk)* 39.661.4 36.762.1 ,0.001
Birth weight (g)* 34416521 33386698 0.36
Birth weight SDS* 0.161.07 1.3561.18 ,0.001
Neonatal BMI SDS* 20.0561.38 1.1461.17 ,0.001
Birth height SDS* 0.5861.28 1.0861.41 0.057
Birth head circumference SDS* 0.3361.02 0.8761.02 0.005
Tricep skinfold (cm)* 4.0560.68 4.7861.16 ,0.001
Subscapular skinfold (cm)* 4.7761.15 5.9661.58 ,0.001
Male sex 25/52 (48.1%) 32/65 (49.2%) 0.90
Special care baby unit admission 1/51 (2%) 28/65 (43.1%) ,0.001
*Values are expressed as means6SD.
Continuous variables were compared at baseline using independent student’s t test; categorical variables were compared using Chi squared test.
doi:10.1371/journal.pone.0074068.t001
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Statistical Analysis
A power calculation, which assumed 65 subjects in the T1DM
group, and 52 subjects in the control group, and a standard
deviation of 25OHD of 17 nmol/l (based upon the average of 5
measures during pregnancy across trimesters and seasons),
indicated that there was over 80% power to detect a difference
in mean total 25OHD of 9 nmol/L between the two groups.
Statistical analysis was carried out using the SPSS statistical
software package version 18.0 (SPSS Inc., Chicago, IL, USA).
Variables not normally distributed were log transformed to natural
logarithms prior to analysis to allow for parametric testing. Both
the control and T1DM groups were compared by independent
Students t test or x2 test, as appropriate. Intergroup comparisons
in 25OHD analysis were performed with paired samples t test and
one-way repeated measures ANOVA, as appropriate. Post hoc
comparisons were made using Tukey to test for specific
comparisons within groups between time-points. Correlations
between continuous variables were assessed by Pearson’s coeffi-
cients for correlations. Multivariate models for cord blood 25OHD
and HbA1c were estimated based on both maternal and neonatal
measures using multiple linear regression.
Results
Clinical Characteristics and Pregnancy Outcomes of
Study Participants
Characteristics of study participants are shown in Table 1.
Control and T1DM groups were not significantly different in age
or number of previous miscarriages. BMI at booking was higher in
the women with T1DM, this difference was approaching
significance. While there was no significant differences between
the groups when parity was ,2, at a parity $2, the control group
was significantly higher. There were significantly fewer cigarette
smokers within the T1DM group. As expected, the T1DM group
exhibited significantly higher HbA1c levels, and also had
significantly increased incidence of preeclampsia. Delivery gesta-
tional age was significantly lower for babies born to mothers with
T1DM; this may explain why the rate of admission to special care
baby units was significantly increased within this group. Neonatal
birth weight (g) and sex did not differ between the two groups.
However, tricep and subscapular skinfold thickness were both
significantly greater in babies born to women with T1DM. Birth
weight SDS and neonatal BMI SDS were both significantly higher
in babies born to mothers with T1DM, as was birth head
circumference SDS; additionally, birth height SDS was higher in
these babies, this difference was approaching significance.
Vitamin D Analysis
Maternal and cord blood deficiency and
insufficiency. Table 2 shows the number and percentage of
pregnant women with 25OHD deficiency/insufficiency based on
the current values relating to bone health. This information is
presented to indicate the prevalence of vitamin D deficiency
(insufficiency) in control and T1DM women according to stage of
pregnancy. The results in this table have not been analysed with
respect to season and observed differences in T1DM and control
women are, therefore, due to differences in season of sampling.
Table 2 shows that vitamin D deficiency, defined as 25OHD
levels ,25 nmol/L, was apparent in both the control and the
T1DM groups across the entire pregnancy. Greater than 90% of
pregnant women were classified as insufficient at each time-point,
regardless of whether they had T1DM or not. This meant that
,10% of this pregnant population were at a sufficient level at
some point throughout pregnancy.
Similar to maternal vitamin D levels, the neonates had a high
incidence of 25OHD deficiency at birth, with 28–32% exhibiting
severe deficiency. All babies had vitamin D levels ,50 nmol/L,
indicating complete lack of sufficiency within this population
(Table 2).
Levels of 25OHD in T1DM subjects and controls within
seasons. There was no significant difference in mean 25OHD
levels between controls and women with T1DM. Also, when
compared within season, levels of vitamin D were similar between
the two groups, with a significant difference between the two
groups only apparent in Autumn [control group vs. T1DM group
(nmol/L6SD); 31.76618.41 vs. 39.12617.34, p=0.031].
Seasonal variation in 25OHD levels was evident. As expected,
Summer 25OHD levels were significantly higher than Winter and
Spring in both the control [Summer vs. Winter (nmol/L6SD);
43.12615.29 vs. 31.04621.50, p=0.043; Summer vs. Spring
(nmol/L6SD); 43.12615.29 vs. 26.55616.53, p=0.003] and
T1DM [Summer vs. Winter (nmol/L6SD); 48.48620.51 vs.
29.19614.42, p,0.001; Summer vs. Spring (nmol/L6SD);
48.48620.51 vs. 31.58615.01, p,0.001] groups. Additionally,
the T1DM group had evidently higher 25OHD levels in the
Autumn months compared to the Winter [Autumn vs. Winter
(nmol/L6SD); 39.12617.34 vs. 29.19614.42, p=0.013]. Despite
these significant seasonal differences, mean levels in both groups
within each season were still below the sufficiency level of
75 nmol/L.
Levels of 25OHD in women with T1DM at the final stage
of pregnancy, post-delivery and within cord blood. Within
season, 25OHD levels from the T1DM group were compared
between samples taken at the final stage of pregnancy, post-
delivery and from cord blood (Figure 1A). In Spring and Winter,
25OHD levels at the final stage of pregnancy were significantly
greater than post-delivery. Further, in Autumn, Winter and
Spring, there was a significant correlation between 25OHD in
final pregnancy and post-delivery samples (r = 0.989, 0.913, 0.906;
all p,0.001). In all seasons, 25OHD levels at the final stage of
pregnancy were significantly greater than those of cord blood.
Again, in all seasons there was a significant correlation between
25OHD in final pregnancy and cord blood samples (Spring
r = 0.979; Summer 0.998; Autumn 0.877; Winter 0.874; all
p,0.002). Furthermore, within Spring, Winter and Autumn,
post-delivery 25OHD levels were significantly greater than cord
blood levels.
Correlations between maternal serum vitamin D levels
and maternal and neonatal outcomes. Table 3 shows
correlations between maternal serum 25OHD levels and maternal
and neonatal outcomes. Maternal 25OHD at booking was
significantly positively correlated with maternal 25OHD at
trimesters 2 and 3 for both control and T1DM subjects. A similar
significant positive association was seen between 25OHD at
trimester 2 and trimester 3 in both groups.
In the T1DM group, HbA1c at booking was significantly
negatively correlated with maternal 25OHD at all 3 timepoints.
Trimester 2 HbA1c was also significantly negatively associated with
25OHD at trimester 2 for the T1DM group and approaching
significance at trimester 3. In the control group, birth weight (g)
was significantly positively correlated with trimester 2 maternal
25OHD. The associations between maternal 25OHD and both
neonatal BMI SDS and birth height SDS were approaching
significance at trimester 2 and reached significance at trimester 3,
in the T1DM group.
Correlations between cord blood vitamin D levels and
maternal and neonatal outcomes. Maternal 25OHD corre-
Vitamin D Status in Type I Diabetic Pregnancy
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lated positively with cord 25OHD at all 3 trimesters in the T1DM
group (Table 3) and at trimester 3 in the control group.
In the T1DM group, maternal HbA1c at booking and trimester
2 significantly negatively correlated with cord 25OHD; as did
neonatal BMI SDS. Additionally, within this group, the associa-
tion between cord 25OHD and birth height SDS was approaching
significance.
Impact of maternal BMI at booking on maternal and cord
vitamin D levels in women with T1DM. In view of the trend
towards a significant increase in BMI at booking in women with
T1DM vs. controls (Table 1), the impact of maternal BMI at
booking (normal weight BMI ,25 kg/m2 vs. obese BMI .30 kg/
m2) on maternal and cord vitamin D levels in the T1DM women
was examined. Levels of 25OHD were similar at booking and
trimester 2 (data not shown), and in the final pregnancy sample
between the two BMI groups (Figure 1B). However, 25OHD
levels within cord blood were significantly lower for women
classified as obese at booking compared with those classified as
normal weight (Figure 1B). Multiple linear regression analysis
indicated that maternal trimester 3 vitamin D, (B = 0.462;
p,0.001) and obese BMI at booking (B=25.132; p=0.013)
significantly impacted on cord 25OHD levels. However, due to
the observed independent interaction between BMI at booking
and maternal trimester 3 25OHD (p=0.016), the impact of these
variables on cord blood 25OHD levels should be interpreted with
caution. Maternal age at delivery, subscapular skinfold, triceps
skinfold, SDS BMI and SDS height did not impact significantly on
cord blood vitamin D levels.
Impact of maternal BMI at booking and maternal 25OHD
on HbA1c in women with T1DM. Based on the significant
negative correlations noted between maternal 25OHD and HbA1c
at various trimesters (Table 3), and the significant positive
correlation between maternal BMI at booking and trimester 1
HbA1c (r = 0.312 and p= 0.012), the impact of maternal 25OHD
and BMI at booking on HbA1c in the T1DM women was
examined. Multiple linear regression analysis indicated that
maternal vitamin D at booking (B=20.015; p=0.011) and obese
BMI at booking (B= 0.566; p=0.045), both had a significant
independent impact on HbA1c at booking. Also, maternal
Table 2. Vitamin D deficiency and insufficiency of pregnant women and neonates, split by maternal diabetes, using various cut-off
levels.
Pregnant women
Gestation and level of vitamin D deficiency Control group T1DM group
n % n %
#14 weeks
,12.5 nmol/l 1 4.5 1 1.8
,25 nmol/l 10 45.5 9 16.4
,50 nmol/l 16 72.7 41 74.5
,75 nmol/l 20 90.9 50 90.9
,100 nmol/l 22 100.0 54 98.2
.14,28 weeks
,12.5 nmol/l 2 5.0 1 1.5
,25 nmol/l 21 52.5 19 29.2
,50 nmol/l 34 85.0 46 70.8
,75 nmol/l 39 97.5 61 93.8
,100 nmol/l 40 100.0 65 100.0
$28 weeks
,12.5 nmol/l 6 11.5 3 4.8
,25 nmol/l 26 50.0 28 45.2
,50 nmol/l 45 86.5 51 82.3
,75 nmol/l 51 98.1 62 100.0
,100 nmol/l 52 100.0 62 100.0
Pregnant women
Neonatal level of vitamin D deficiency Control group T1DM group
n % n %
Cord blood
,12.5 nmol/l 8 32.0 16 28.6
,25 nmol/l 23 92.0 44 78.6
,50 nmol/l 25 100.0 56 100.0
Data are cumulative n and cumulative %.
doi:10.1371/journal.pone.0074068.t002
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trimester 2 vitamin D (B=20.01; p=0.017) independently
impacted on HbA1c at trimester 2.
Discussion
The current study has provided evidence that, in T1DM
pregnancy, low 25OHD levels persist throughout gestation and
post-delivery. In addition, the study findings indicate that cord
blood vitamin D levels correlate with those of the mother, and are
significantly lower in obese women than in their normal weight
counterparts. Maternal vitamin D levels were also found to exhibit
a significant negative relationship with HbA1c levels, supporting a
role for this vitamin in maintaining glycaemic control.
The findings of the current study that, in women with T1DM,
low vitamin D levels are evidenced throughout gestation are in
agreement with previous groups who have reported compromised
vitamin D status in pregnancy [5]. The current study found little
evidence of significant differences between the control and T1DM
groups during pregnancy; mean levels were similar, as were
seasonal levels for Spring, Summer and Winter. A previous report
has provided some evidence that pregnant women with T1DM
had lower levels than pregnant women without diabetes; however,
due to differences in analyses it is difficult to make direct
comparisons with this study [27]. The present analysis further
determined that, cord blood vitamin D levels correlated with those
of the mother, and were, thus, predominantly deficient/insuffi-
cient and, in women with T1DM, low vitamin D levels persisted
post-delivery. These findings support the contention that mea-
surement of vitamin D levels prior to, and during pregnancy,
should be recommended, and that vitamin D supplementation be
initiated when deficiency is confirmed. Even given the lack of
evidence supporting a causal link between low vitamin D and a
range of non-bone health outcomes, assessment and supplemen-
tation are essential with respect to the optimal bone health of both
mother and off-spring. This is particularly important for women at
high-risk of deficiency [15]. Recent recommendations from the
Figure 1. Impact of maternal vitamin D status and BMI on
neonatal vitamin D levels. (A) Within season comparisons of
mean 25OHD levels (nmol/L) in final pregnancy (wk 31–38),
post-delivery and cord blood samples from T1DM women and
their neonates (n=29) Error bars indicate S.D. Comparisons were
performed using paired samples t test: * = vs. final pregnancy sample;
p,0.05;ˆ= vs. post-delivery sample; p,0.05. (B) Comparison of mean
25OHD levels (nmol/L) between normal weight (BMI at
booking ,25 kg/m2; n=22–24) and obese (BMI at booking
.30 kg/m2; n=16–17) T1DM women in the final pregnancy
sample (wk 31–38) and neonatal cord blood. Error bars indicate
S.D. Comparisons were performed using independent student’s t-test:
*p=0.026.
doi:10.1371/journal.pone.0074068.g001
Table 3. Maternal and cord vitamin D levels and their
relationship with maternal and neonatal outcome variables.
Variable Control Group T1DM Group
r p value r p value
Maternal Vitamin D booking
Vitamin D trimester 2 0.92 ,0.001 0.46 ,0.001
Vitamin D trimester 3 0.76 ,0.001 0.38 0.005
HbA1c booking 20.16 0.49 20.38 0.004
Maternal Vitamin D trimester 2
Vitamin D trimester 3 0.66 ,0.001 0.64 ,0.001
HbA1c booking 20.11 0.55 20.41 0.001
HbA1c trimester 2 0.06 0.76 20.28 0.03
Birth weight (g) 0.39 0.01 0.02 0.87
Neonatal BMI SDS 0.17 0.31 20.24 0.07
Birth height SDS 20.06 0.73 0.23 0.08
Maternal Vitamin D trimester 3
HbA1c booking 20.16 0.35 20.25 0.05
HbA1c trimester 2 20.13 0.42 20.22 0.08
Neonatal BMI SDS 0.11 0.43 20.30 0.02
Birth height SDS 20.002 0.99 0.28 0.03
Cord Vitamin D
Neonatal Measure
Neonatal BMI SDS 0.29 0.17 20.31 0.03
Birth height SDS 20.19 0.39 0.26 0.06
Maternal HbA1c
Booking 20.14 0.57 20.44 0.001
Trimester 2 20.39 0.12 20.29 0.03
Trimester 3 20.23 0.29 20.22 0.12
Maternal vitamin D
Booking 0.39 0.26 0.33 0.02
Trimester 2 0.25 0.32 0.46 ,0.001
Trimester 3 0.73 ,0.001 0.84 ,0.001
Correlations between continuous variables were assessed by Pearson’s
coefficients for correlations.
doi:10.1371/journal.pone.0074068.t003
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Institute of Medicine (IOM) advise pregnant and breastfeeding
women in the USA and Canada to supplement with 15 mg/day to
maintain optimal bone health [28]. Department of Health
guidelines in the UK currently recommend pregnant women to
supplement with 10 mg/day to protect against vitamin D
deficiency [29], but this is disputed by some [30]. Hollis et al.,
[30] argue that supplementation of up to 100 mg/day is more
effective at maintaining vitamin D sufficiency throughout preg-
nancy, when compared with 10 and 50 mg/day. In 2011, the UK
Scientific Advisory Committee on Nutrition decided, based on
new data, including the IOM report of Dietary Reference Values,
that there is now sufficient evidence for an update on vitamin D,
which is expected June 2014 [3].
As previously discussed, an inverse relationship between
circulating levels of 25OHD and measures of adiposity has been
reported, most probably due to the storage of cutaneously
synthesized D3, the 25OHD precursor, in subcutaneous adipose
tissue [17,18]. In the current study there was an increase in BMI at
booking in the T1DM group vs. control group (Table 1). When
the impact of maternal BMI at booking on maternal and cord
vitamin D levels in T1DM women was examined, maternal levels
of 25OHD in women with T1DM classified as obese at booking
displayed a trend for being lower. Further, 25OHD levels within
cord blood were significantly lower in neonates from women
classified as obese at booking compared with those classified as
normal weight. Taken together, these results indicate that obese
women with T1DM have lower circulating 25OHD levels and
transfer reduced levels of 25OHD to their off-spring. These
findings are in broad agreement with previous studies in women
without T1DM [20,21], which have reported significantly reduced
cord 25OHD levels in women classified as obese vs. normal weight
pre-pregnancy. While Josefson et al., reported an impact of
maternal age and neonatal adiposity, directly measured by air
displacement plethysmography, on cord vitamin D levels, in the
current study, although neonatal BMI SDS was significantly
negatively correlated with cord 25OHD in subjects with T1DM,
regression analysis indicated that maternal age at delivery and
surrogate measures of neonatal adiposity (subscapular skinfold,
triceps skinfold, and SDS BMI) did not impact significantly on
cord blood 25OHD.
A key finding of the current study is that in T1DM pregnancy,
maternal vitamin D levels exhibit an independent inverse
relationship with HbA1c levels. Potential mechanisms by which
vitamin D might influence glycaemic control in T1DM include,
the impact of this vitamin on intracellular calcium regulation and,
thus, glucose transport in target tissues, influences on insulin
receptor expression and the effect of vitamin D on systemic
inflammation associated with insulin resistance [31,32]. While
traditionally associated with T2DM, the importance of insulin
resistance in the etiology of T1DM is being increasingly
recognised, albeit that the underlying mechanisms may differ
from those in T2DM [33,34]. Low vitamin D levels are associated
with insulin resistance in T2DM and its co-morbidities [35]. With
respect to a causal link between vitamin D repletion and improved
glucose homeostasis, limited studies have reported substantial
improvements in glycaemic control (HbA1c levels) in T1DM
patients who achieved higher circulating 25OHD levels via
supplementation [36,37]. The results of a recent systematic review
suggest a weak effect of vitamin D supplementation in reducing
fasting glucose and improving insulin resistance in patients with
T2DM or impaired glucose tolerance [38]. The magnitude of the
reduction in fasting glucose seen in this analysis was small leading
the authors to conclude that, given that HbA1c did not change in
patients with impaired glucose tolerance or T2DM, this is of
debatable clinical significance.
One of the limitations of the current study is that it is
observational. Clearly, prospective clinical randomised controlled
trials of vitamin D supplementation are required to evaluate and
clarify the association between vitamin D status and glycaemic
control in T1DM pregnancy. A further limitation is that
information is not available on dietary or supplemental vitamin
D intake, in these women. However, the low levels of vitamin D
found in both the control and T1DM groups would appear to
argue against the widespread use of augmented intake.
In conclusion, the finding that vitamin D dependent processes
may be negatively impacted by maternal nutritional status and
obesity in a T1DM cohort is a significant one and provides further
evidence that population-based interventions aimed at reducing
obesity and improving pre-pregnancy and gestational vitamin D
status are needed. Given the safety of vitamin D, the low cost of
supplementation and its requirement for optimal bone health (and
potentially other health outcomes) in both the mother and off-
spring, the findings of the current study support the case for
determining vitamin D status and, if necessary, administering
vitamin D in T1DM pregnancy.
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